A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

NCT06085521 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: LNK01001 Dose A
DRUG: LNK01001 Dose B
DRUG: placebo

Sponsor

Lynk Pharmaceuticals Co., Ltd